Journal of Medicinal Chemistry
ARTICLE
(13) Richelda, R.; Ronchetti, D.; Baldini, L.; Cro, L.; Viggiano, L.;
Marzella, R.; Rocchi, M.; Otsuki, T.; Lombardi, L.; Maiolo, A. T.; Neri,
A. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple
myeloma involves the fibroblast growth-factor receptor 3 gene. Blood
1997, 90, 4062–4070.
(14) Intini, D.; Baldini, L.; Fabris, S.; Lombardi, L.; Ciceri, G.;
Maiolo, A. T.; Neri, A. Analysis of FGFR3 gene mutations in multiple
myeloma patients with t(4;14). Br. J. Hamaetol. 2001, 114, 362–364.
(15) Cappellen, D.; De Oliveira, C.; Ricol, D.; De Medina, S. G. D.;
Bourdin, J.; Sastre-Garau, X.; Chopin, D.; Thiery, J. P.; Radvanyi, F.
Frequent activating mutations of FGFR3 in human bladder and cervix
carcinomas. Nature Genet. 1999, 23, 18–20.
(25) Jacquemier, J.; Adelaide, J.; Parc, P.; Penault-Llorca, F.;
Planche, J.; deLapeyriere, O.; Birnbaum, D. Expression of the FGFR1
gene in human breast-carcinoma cells. Int. J. Cancer 1994, 59, 373–378.
(26) Jaakkola, S.; Salmikangas, P.; Nylund, S.; Partanen, J.; Arm-
strong, E.; Pyrhonen, S.; Lehtovirta, P.; Nevanlinna, H. Amplification of
fgfr4 gene in human breast and gynecological cancers. Int. J. Cancer
1993, 54, 378–382.
(27) Theillet, C.; Adelaide, J.; Louason, G.; Bonnet-Dorion, F.;
Jacquemier, J.; Adnane, J.; Longy, M.; Katsaros, D.; Sismondi, P.;
Gaudray, P.; et al. FGFRI and PLAT genes and DNA amplification at
8p12 in breast and ovarian cancers. Genes, Chromosomes Cancer 1993, 7,
219–226.
(16) Billerey, C.; Chopin, D.; Aubriot-Lorton, M.-H.; Ricol, D.; Gil
Diez de Medina, S.; Van Rhijn, B.; Bralet, M.-P.; Lefrere-Belda, M.-A.;
Lahaye, J.-B.; Abbou, C. C.; Bonaventure, J.; Zafrani, E. S.; Van Der
Kwast, T.; Thiery, J. P.; Radvanyi, F. Frequent FGFR3 mutations in
papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 2001,
158, 1955–1959.
(17) Gomez-Roman, J. J.; Saenz, P.; Cuevas Gonzalez, J.; Escuredo,
K.; Santa Cruz, S.; Junquera, C.; Simon, L.; Martinez, A.; Gutierrez
Banos, J. L.; Lopez-Brea, M.; Esparza, C.; Val-Bernal, J. F. Fibroblast
growth factor receptor 3 is overexpressed in urinary tract carcinomas
and modulates the neoplastic cell growth. Clin. Cancer Res. 2005, 11,
459–465.
(18) Jang, J. H.; Shin, K. H.; Park, J. G. Mutations in fibroblast
growth factor receptor 2 and fibroblast growth factor receptor 3 genes
associated with human gastric and colorectal cancers. Cancer Res. 2001,
61, 3541–3543.
(19) Takeda, M.; Arao, T.; Yokote, H.; Komatsu, T.; Yanagihara, K.;
Sasaki, H.; Yamada, Y.; Tamura, T; Fukuoka, K.; Kimura, H.; Saijo, N.;
Nishio, K. AZD2171 shows potent antitumor activity against gastric
cancer over-expressing fibroblast growth factor receptor 2/keratinocyte
growth factor receptor. Clin. Cancer Res. 2007, 13, 3051–3057.
(20) Kunii, K.; Davis, L.; Gorenstein, J.; Hatch, H.; Yashiro, M.; Di
Bacco, A.; Elbi, C.; Lutterbach, B. FGFR2-amplified gastric cancer cell
lines require FGFR2 and Erbb3 Signaling for Growth and Survival.
Cancer Res. 2008, 68, 2340–2348.
(28) Adnane, J.; Gaudray, P.; Dionne, C. A.; Crumley, G.; Jaye, M.;
Schlessinger, J.; Jeanteur, P.; Birnbaum, D.; Theillet, C. BEK and FLG,
two receptors to members of the FGF family, are amplified in subsets of
human breast cancers. Oncogene 1991, 6, 659–663.
(29) Elsheikh, S. E.; Green, A. R.; Lambros, M. B. K.; Turner, N. C.;
Grainge, M. J.; Powe, D.; Ellis, I. O.; Reis-Filho, J. S. FGFR1 amplifica-
tion in breast carcinomas: a chromogenic in situ hybridisation analysis.
Breast Cancer Res. 2007, 9, R23.
(30) Valladares, A.; Garcia Hernandez, N.; Salamanca Gomez, F.;
Curiel-Quezada, E.; Madrigal-Bujaidar, E.; Vergara, M. D.; Sierra
Martinez, M.; Arenas Aranda, D. J. Genetic expression profiles and
chromosomal alterations in sporadic breast cancer in Mexican women.
Cancer Genet. Cytogenet. 2006, 170, 147–151.
(31) Fioravanti, L.; Cappelletti, V.; Coradini, D.; Miodini, P.;
Borsani, G.; Daidone, M. G.; Di Fronzo, G. int-2 oncogene amplification
and prognosis in node-negative breast carcinoma. Int. J. Cancer 1997, 74,
620–624.
(32) Hui, R.; Campbell, D. H.; Lee, C. S. L.; McCaul, K.; Horsfall,
D. J.; Musgrove, E. A.; Daly, R. J.; Seshadri, R.; Sutherland, R. L. EMS1
amplification can occur independently of CCND1 or INT-2 amplifica-
tion at 11q13 and may identify different phenotypes in primary breast
cancer. Oncogene 1997, 15, 1617–1623.
(33) Berns, E. M. J. J.; Foekens, J. A.; van Staveren, I. L.; van Putten,
W. L. J.; de Koning, H. Y. W. C. M.; Portengen, H.; Klijn, J. G. M.
Oncogene amplification and prognosis in breast cancer: relationship
with systemic treatment. Gene 1995, 159, 11–18.
(34) Mayr, D.; Kanitz, V.; Anderegg, B.; Luthardt, B.; Engel, J.;
Lohrs, U.; Amann, G.; Diebold, J. Analysis of gene amplification and
prognostic markers in ovarian cancer using comparative genomic
hybridization for microarrays and immunohistochemical analysis for
tissue microarrays. Am. J. Clin. Pathol. 2006, 126, 101–109.
(35) Seki, A.; Yoshinouchi, M.; Seki, N.; Kodama, J.; Miyagi, Y.;
Kudo, T. Detection of c-erbB-2 and FGF-3 (INT-2) gene amplification
in epithelial ovarian cancer. Int. J. Oncol. 2000, 17, 103–106.
(36) Rubin, J. S.; Qiu, L.; Etkind, P. Amplification of the Int-2 gene in
head and neck squamous cell carcinoma. J. Laryngol. Otol. 1995,
109, 72–76.
(21) Pollock, P. M.; Gartside, M. G.; Dejeza, L. C.; Powell, M. A.;
Mallon, M. A.; Davies, H.; Mohammadi, M.; Futreal, P. A.; Stratton,
M. R.; Trent, J. M.; Goodfellow, P. J. Frequent activating FGFR2
mutations in endometrial carcinomas parallel germline mutations asso-
ciated with craniosynostosis and skeletal dysplasia syndromes. Oncogene
2007, 26, 7158–7162.
(22) Weiss, J. M.; Sos, M. L.; Seidel, D.; Peifer, M.; Zander, T.;
Heuckmann, J. M.; Ullrich, R. T.; Menon, R.; Maier, S.; Soltermann, A.;
Moch, H.; Wagener, P.; Fischer, F.; Heynck, S.; Koker, M.; Sch€ottle, J.;
Leenders, F.; Gabler, F.; Dabow, I.; Querings, S.; Heukamp, L. C.; Balke-
Want, H.; Ansꢀen, S.; Rauh, D.; Baessmann, I.; Altm€uller, J.; Wainer, Z.;
Conron, M.; Wright, G.; Russell, O.; Solomon, B.; Brambilla, E.;
Brambilla, C.; Lorimier, P.; Sollberg, S.; Brustugun, O. T.; Engel-Riedel,
W.; Ludwig, C.; Petersen, I.; S€anger, J.; Clement, J.; Groen, H.; Timens,
W.; Sietsma, H.; Thunnissen, E.; Smit, E.; Heideman, D.; Cappuzzo, F.;
Ligorio, C.; Damiani, S.; Hallek, M.; Beroukhim, R.; Pao, W.; Klebl, B.;
Baumann, M.; Buettner, R.; Ernestus, K.; Stoelben, E.; Wolf, J.;
N€urnberg, P.; Perner, S.; Thomas, R. K. Frequent and Focal FGFR1
Amplification Associates with Therapeutically Tractable FGFR1 De-
pendency in Squamous Cell Lung Cancer. Sci. Transl. Med. 2010, 2,
62–93.
(37) Hu, L.; Sham, J. S. T.; Xie, D.; Wen, J.-M.; Wang, W.-S.; Wang,
Y.; Guan, X.-Y. Up-regulation of fibroblast growth factor 3 is associated
with tumor metastasis and recurrence in human hepatocellular carcino-
ma. Cancer Lett. 2007, 252, 36–42.
(38) Tsou, A. P.; Wu, K. M.; Tsen, T. Y.; Chi, C. W.; Chiu, J. H.; Lui,
W. Y.; Hu, C. P.; Chang, C.; Chou, C. K.; Tsai, S. F. Parallel hybridization
analysis of multiple protein kinase genes: identification of gene expres-
sion patterns characteristic of human hepatocellular carcinoma. Geno-
mics 1998, 50, 331–340.
(23) Reis-Filho, J. S.; Simpson, P. T.; Turner, N. C.; Lambros, M. B.;
Jones, C.; Mackay, A.; Grigoriadis, A.; Sarrio, D.; Savage, K.; Dexter, T.;
Iravani, M.; Fenwick, K.; Weber, B.; Hardisson, D.; Schmitt, F. C.;
Palacios, J.; Lakhani, S. R.; Ashworth, A. FGFR1 emerges as a potential
therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 2006,
12, 6652–6662.
(39) Gerald, J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.;
Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F.
Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase
Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-
Substituted Indolinone (BIBF 1120). J. Med. Chem. 2009, 52, 4466–
4480.
(24) Penault-Llorca, F.; Bertucci, F.; Adelaide, J.; Parc, P.; Coulier,
F.; Jacquemier, J.; Birnbaum, D.; deLapeyriere, O. Expression of FGF
and FGF receptor genes in human breast cancer. Int. J. Cancer 1995,
61, 170–176.
(40) Renhowe, P. A.; Pecchi, S.; Shafer, C. M.; Machajewski, T. D.;
Jazan, E. M.; Taylor, C.; Antonios-McCrea, W.; McBride, C. M.; Frazier,
K.; Wiesmann, M.; Lapointe, G. R.; Feucht, P. H.; Warne, R. L.;
Heise, C. C.; Menezes, D.; Aardalen, K.; Ye, H.; He, M.; Le, V.; Vora, J.;
7082
dx.doi.org/10.1021/jm2006222 |J. Med. Chem. 2011, 54, 7066–7083